Assenagon Asset Management S.A. Increases Stock Holdings in Protara Therapeutics, Inc. $TARA

Assenagon Asset Management S.A. raised its stake in Protara Therapeutics, Inc. (NASDAQ:TARA) by 84.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 567,621 shares of the company’s stock after purchasing an additional 259,287 shares during the period. Assenagon Asset Management S.A.’s holdings in Protara Therapeutics were worth $2,957,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Virtu Financial LLC acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at $368,000. ADAR1 Capital Management LLC lifted its position in Protara Therapeutics by 3,127.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock valued at $6,059,000 after acquiring an additional 1,101,576 shares during the last quarter. XTX Topco Ltd acquired a new position in Protara Therapeutics in the fourth quarter valued at $615,000. Sphera Funds Management LTD. purchased a new position in shares of Protara Therapeutics during the fourth quarter worth about $3,464,000. Finally, Quadrature Capital Ltd grew its holdings in shares of Protara Therapeutics by 39.4% during the fourth quarter. Quadrature Capital Ltd now owns 24,184 shares of the company’s stock worth $129,000 after purchasing an additional 6,838 shares during the last quarter. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Stock Performance

NASDAQ TARA opened at $3.82 on Wednesday. The firm has a market cap of $214.68 million, a PE ratio of -2.85 and a beta of 1.45. Protara Therapeutics, Inc. has a one year low of $2.77 and a one year high of $7.82. The firm’s fifty day moving average is $4.62 and its two-hundred day moving average is $5.34.

Protara Therapeutics (NASDAQ:TARA) last announced its earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. Research analysts predict that Protara Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Oppenheimer lifted their price target on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. JPMorgan Chase & Co. reduced their price objective on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Finally, Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.25.

Protara Therapeutics Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.